Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03670342|
Recruitment Status : Recruiting
First Posted : September 13, 2018
Last Update Posted : September 27, 2018
Hypothesis: To estimate the proportion of locally advanced, recurrent or metastatic nasopharyngeal cancer patients which show high somatostatin receptor density (SUVmax >10) on Ga-68 DOTATATE imaging.
Galium-68 DOTATATE: PET imaging will be performed with a PET/CT scanner. Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
The standardized uptake value (SUV) will be used in the interpretation of the Ga-68 DOTATATE scans. The values gathered will be used as an estimate of the somatostatin receptor density. A patient will be considered to have an overall high somatostatin receptor density if the average SUVmax of all the representative lesions is more than 10.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||15 participants|
|Official Title:||Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer|
|Actual Study Start Date :||August 20, 2015|
|Estimated Primary Completion Date :||August 20, 2020|
|Estimated Study Completion Date :||August 20, 2025|
- Number of NPC patients with high somatostatin receptor density [ Time Frame: 60 minutes ]High somatostatin receptor density is when average maximum standardized uptake value (SUVmax) of all the representative lesions is more than 10 on Ga-68 DOTATATE imaging
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03670342
|Contact: Wen Long Nei||+65 6436 firstname.lastname@example.org|
|National Cancer Centre||Recruiting|
|Singapore, Singapore, 169610|
|Principal Investigator:||Wen Long Nei||National Cancer Centre, Singapore|